These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28429551)

  • 41. Dietary calcium intake does not meet the nutritional requirements of children with chronic kidney disease and on dialysis.
    McAlister L; Silva S; Shaw V; Shroff R
    Pediatr Nephrol; 2020 Oct; 35(10):1915-1923. PubMed ID: 32385527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phosphate Binders and Targets Over Decades: Do We have it Right Now?
    Marcuccilli M; Chonchol M; Jovanovich A
    Semin Dial; 2017 Mar; 30(2):134-141. PubMed ID: 28064444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
    BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease.
    Yang X; Bai Q; Li Y; Liu H; Guo H; Zhang X
    JPEN J Parenter Enteral Nutr; 2018 May; 42(4):766-777. PubMed ID: 28777915
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders.
    Locatelli F; Del Vecchio L
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):489-99. PubMed ID: 25804298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
    Hanafusa N
    Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention and treatment of hyperphosphatemia in chronic kidney disease.
    Vervloet MG; van Ballegooijen AJ
    Kidney Int; 2018 May; 93(5):1060-1072. PubMed ID: 29580635
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacology, efficacy and safety of oral phosphate binders.
    Hutchison AJ; Smith CP; Brenchley PE
    Nat Rev Nephrol; 2011 Sep; 7(10):578-89. PubMed ID: 21894188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treating hyperphosphatemia - current and advancing drugs.
    Ketteler M; Liangos O; Biggar PH
    Expert Opin Pharmacother; 2016 Oct; 17(14):1873-9. PubMed ID: 27643443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phosphate binders in CKD: bad news or good news?
    Drüeke TB; Massy ZA
    J Am Soc Nephrol; 2012 Aug; 23(8):1277-80. PubMed ID: 22797178
    [No Abstract]   [Full Text] [Related]  

  • 56. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
    Di Iorio B; Bellasi A; Russo D;
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality.
    McCullough PA
    Cardiorenal Med; 2021; 11(3):123-132. PubMed ID: 34120113
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.
    Liu L; Wang Y; Chen H; Zhu X; Zhou L; Yang Y
    Ren Fail; 2014 Sep; 36(8):1244-52. PubMed ID: 25019348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.